Related coverage linked through entity extraction aliases.
Jul 20, 2026
New research reveals how TB bacteria resist drugs via PE/PPE proteins and evade immune defenses by stiffening cell membranes. TB remains the leading infectious killer, with 1.23 million deaths in 2024.
Mar 19, 2026
NEJM-published Phase 2a results show alpibectir enabled a two-thirds dose reduction of ethionamide and clinical proof of concept in pulmonary TB. First patient dosed in the Phase 2b STEP2C Stage 3 trial within UNITE4TB.
May 29, 2026
Kenya is building local vaccine manufacturing capacity through a WHO-supported mRNA technology transfer project and a three-phase strategy focused on childhood vaccines. The country aims to reduce reliance on imports, with a fill-and-finish facility in Embakasi expected by 2027 and first locally produced vaccines by 2028.
Jun 10, 2026
Trial: VPM1002/Immuvac show limited overall TB protection but up to 50.4% efficacy vs extrapulmonary TB. Modeling: blocking asymptomatic TB key to long-term vaccine impact. Also: STEP-TB safety study and CDC Asia funding.
Jul 17, 2026
RCB Faridabad announces three openings: a ₹1.30L/month Post Doc EIR fellowship, a Project Associate II for TB research, and an apprenticeship for life sciences graduates. Deadlines: Feb 25, Jun 8-9, Jul 24, 2026.
Jul 15, 2026
A single-center study of 95 chronic kidney disease patients on hemodialysis found the Cy-TB skin test agreed completely with standard IGRA testing for latent tuberculosis, with an overall prevalence of 4.2%. Early dialysis phase (<6 months) was a strong predictor of positivity, suggesting a potential priority screening window, though larger confirmatory studies are needed.
May 09, 2026
Three advances in TB diagnostics: a portable $300 device delivering results in 30 minutes, a Quick DNA kit detecting drug resistance in 5 minutes, and an ultrasensitive test finding TB DNA in 12-16% of hospitalized US patients.
Mar 28, 2026
India launches ₹10,000 crore Biopharma SHAKTI initiative to transform from generics manufacturing to innovation-led biologics leadership. The national mission aims to capture 5% of global biopharmaceutical market while addressing structural challenges in drug discovery and AI adoption.
Mar 26, 2026
A vaccine and two novel tuberculosis treatments are advancing through Phase III trials, marking renewed momentum in TB research. Tuberculosis claims over 1.25 million lives annually with 10.6 million new cases in 2023, while current treatments face challenges of high pill burden, toxicity, and rising resistance.
Mar 24, 2026
The World Health Organization has recommended new portable TB diagnostic tests that deliver results in under an hour, while researchers developed an inhalable nanoparticle treatment that could replace daily pills. TB remains the world's deadliest infectious disease, killing 1.2 million people in 2024 despite being preventable and curable.
Mar 19, 2026
Researchers have developed an inhalable nanoparticle system for delivering rifampin directly to the lungs, potentially reducing tuberculosis treatment from daily to once-weekly dosing while lowering side effects and improving drug effectiveness.
Mar 12, 2026
BioVersys has dosed the first patient in a Phase 2b trial evaluating alpibectir-ethionamide (AlpE) in combination with first-line TB drugs, following promising Phase 2a results published in the New England Journal of Medicine.
Mar 11, 2026
Researchers have created a nasal vaccine platform that protects mice against flu, COVID-19, SARS, and bacterial infections by activating both innate and adaptive immune systems, offering a fundamentally different approach to disease prevention.
Mar 03, 2026
Healthcare systems worldwide are addressing polypharmacy as a major public health issue, with new guidance emphasizing person-centered medication reviews and risk mitigation strategies across multiple clinical settings including infectious disease care.
Feb 20, 2026
Vir Biotechnology is set to report Q4 2025 earnings on Feb 23, 2026, with analysts expecting revenue of $19.91-$23.18 million and a loss of $0.41-$0.50 per share, marking a 61% year-over-year revenue increase.
Feb 11, 2026
Obesity contributes to about 1 in every 4 infectious disease deaths in the United States and 1 in 10 globally, according to a major study. People with obesity face 70% higher risk of hospitalization or death from infections, with risk tripling at severe obesity levels.
